应用善宁治疗重症急性胰腺炎

目的评估奥曲肽(善宁)在重症急性胰腺炎患者中的治疗作用。方法53例重症急性胰腺炎患者随机分成两组:对照组予以常规方法治疗;治疗组在常规方法基础上加用善宁治疗。观察两组患者血白细胞、血淀粉酶、血糖、血钙恢复时间和C反应蛋白的变化,以及两组患者住院时间、并发症和死亡率的发生情况。结果治疗组患者血白细胞、血淀粉酶、血糖恢复时间明显短于对照组(P<0.05),C反应蛋白第4天和第7天明显低于对照组(P<0.05);住院时间治疗组明显短于对照组(21.1±15.9vs33.5±16.4,P<0.05);治疗组和对照组并发症总发生率分别为53.5%和80.0%(P<0.05),死亡率分别为10.7%和32.0%(P<0.05)。结论早期应用善宁不仅能够改善患者的临床症状和生化指标,还能减轻患者的全身炎症反应,降低多器官衰竭的发生,改善预后。

Application of Sandostatin in the treatment of severe acute pancreatitis

Obejective To evaluate the efficacy of Sandostatin in the treatment of severe acute pancreatitis in a case-control study. Methods 53 patients with severe acute pancreatitis were randomly assigned to conventional treatment either without(control group) or with Sandostatin (treatment group). Symptom and signs, blood amylase, WBC, glucose, calcium and C reaction protein, length of hospital stay , complication rate and mortality were observed in two group. Results Symptom and signs, blood amylase,WBC and glucose were recovered more quickly among the treatment group (P <0.05); C reaction protein was lower in the fourth and seventh day in the treatment group (P <0.05) -,The complication rate was lower in the treatment group than in the control group (53.5% vs 80.0%, P <0.05). The hospital stay was shorter in the treatment group (20.6 vs 33.1 days, P <0.05). Three patients died in the treatment group and eight in the control group (10.7%vs32.0% ,P < 0.05).Conclusion These results suggest that Sandostatin given early in the course of the disease may have a beneficial effect in the treatment of severe acute pancreatitis.